HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs ® to Accelerate Development of RNA-Guided Therapeutics Platform
LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)-- HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has relocated its U.S. site to Lilly Gateway Labs in San Diego, California, which is operated in partnership with Alexandria Real Estate Equities, Inc.
'Moving our U.S. site to Lilly Gateway Labs marks an important step in the scale-up of our operations,' said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics.
Share
'Moving our U.S. site to Lilly Gateway Labs marks an important step in the scale-up of our operations,' said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. 'The facility offers world-class infrastructure and access to a dynamic scientific environment, providing an ideal setting to continue to advance our RNA-guided therapeutics platform, which is designed to reprogram the root causes of disease with unmatched precision, speed and scalability.'
Lilly Gateway Labs, which is part of the Lilly Catalyze360™ model, is a best-in-class innovation hub that connects early-stage biotech companies to the power of Lilly's expertise. The site offers cutting-edge laboratory space, operational support and access to an evolving ecosystem of biotech innovators.
HAYA's San Diego office plays a central role in the company's laboratory operations, with a strong focus on advanced multi-modal functional genomics, one of the key components of HAYA's proprietary platform and its Regulatory Genome Atlas. The office will also support business and clinical development, including the advancement of HAYA's first-in-class long non-coding RNA (lncRNA)-targeting therapy HTX-001 for heart failure into the clinic with an initial focus on non-obstructive hypertrophic cardiomyopathy.
HAYA recently announced a $65 million Series A financing to accelerate the development of RNA-guided therapeutics that target the regulatory genome to treat chronic and age-related diseases. The round was co-led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company (Lilly) and Alexandria Venture Investments, the venture arm of Alexandria Real Estate Equities, Inc.
At the core of HAYA's platform is the ability to map and decode the regulatory genome. HAYA has built the most comprehensive atlas of the regulatory genome by combining multi-modal functional genomics with proprietary computational and machine learning tools. This allows for the precise identification and modulation of pathogenic cell states across a range of diseases. Last year, HAYA announced a collaboration with Lilly focused on RNA-based drug targets for obesity and related metabolic disorders, making it one of the largest collaborations to date in the regulatory genome field.
With its platform, HAYA is advancing a novel approach to develop next-generation precision medicines, and advance its mission of translating deep genomic, epigenomic and transcriptomic insights into novel disease-modifying therapies with potential to improve patients' outcomes by directly reprogramming the cellular drivers of disease.
HAYA Therapeutics remains fully independent and retains all assets and intellectual property while at Lilly Gateway Labs.
About HAYA Therapeutics
HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. The company is using its innovative platform to gain novel insights into the biology of disease cell states and the long non-coding RNAs (lncRNAs) that regulate them. HAYA's lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues.
HAYA is headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at Lilly Gateway Labs, powered by Alexandria, in San Diego. For more information on the company, please visit our website at www.hayatx.com. Follow us on X and LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Built for America: GE Appliances Completes $180 Million Expansion at Georgia Plant
Latest milestone brings total investment in U.S. manufacturing to $3.5 billion since 2016 LAFAYETTE, Ga., June 11, 2025 /PRNewswire-PRWeb/ -- GE Appliances, a Haier company, today announced the completion of an expanded $180 million investment at its Roper Corporation cooking products plant in LaFayette, Georgia underscoring the company's Built for America commitment to U.S. manufacturing and delivering innovation to American homes. This investment includes an additional $60 million above the previously announced total. Since 2016, GE Appliances – currently rated America's #1 Appliance Company* – has invested over $3.5 billion in new technology and products across its U.S. operations, more than any other competitor. "At GE Appliances, we're investing in American manufacturing – right here in Georgia," said Luther Ingram, executive director and plant manager at Roper Corporation. "By combining advanced automation with the skills and dedication of our local team, we're creating high quality jobs, launching breakthrough products, and ensuring that 'Georgia Made' ranges are being shipped to homes across the country." This investment has enabled the purchase of state-of-the-art equipment, expanded production capacity, and accelerated the launch of innovative new products—most notably the new GE Profile™ induction range, a more accessible and affordable way for consumers to experience induction cooking. The plant's new, high-volume production lines can produce gas, electric, or induction ranges and flex to meet customer demand. New assembly lines feature advanced manufacturing technology, including robotic cells that assemble glass cooktops, program control boards, and rotate units for easier final assembly. Robotics use has more than tripled at Roper, improving efficiency and employee ergonomics. Workforce development programs, including robotics training for employees, are funded in part by a state grant and delivered in partnership with Georgia Northwestern Technical College. The combined investment has added more than 600 new jobs to the plant. "Investments by manufacturers such as GE Appliances at Roper Corporation are a major reason why Georgia boasts a gross regional product (GRP) of $678.2 billion, the 8th highest among U.S. states," said Lloyd Avram, president and CEO for the Georgia Association of Manufacturers. "Georgia's manufacturing sector, employing 426,940 production workers, is responsible for $77 billion of that output." Employment and Investment Impact in Georgia In 2024 alone, GE Appliances spent $235 million with 359 Georgia suppliers, and the company employs 2,650 people in Georgia. GE Appliances' operations, employees and suppliers have a $3 billion impact on Georgia's Gross Domestic Product (GDP), and they have contributed to the creation of 7,500 additional jobs in the state. Opened in 1973, Roper Corporation is the largest employer in Walker County, and one of the largest employers in northwest Georgia. The plant has 15 production lines that produce cooktops, wall ovens and ranges under the Monogram™, Café™, GE Profile™, and GE® brands. The plant is vertically integrated encompassing stamping, paint, enamel, welding, graphics and production – all under one roof. GE Appliances and Roper Corporation are proud participants in the Georgia Department of Economic Development's Georgia Made Program, an initiative that promotes and supports businesses that manufacture products within the state. In 2023, GE Appliances and Roper Corporation celebrated the plant's 50-year legacy of cooking product innovation and dedication to quality and dependability. "Our growth in LaFayette reflects Georgia's vital role in driving U.S. manufacturing forward," Ingram added. "We're not just building appliances—we're building careers, strengthening communities, and powering the future of American industry." About GE Appliances At GE Appliances, a Haier company, we come together to make good things, for life. Headquartered in Louisville, Kentucky, we are a leading U.S. manufacturer of home appliances with 15,500 team members nationwide. GE Appliances, found in half of all U.S. homes, is proud to be rated America's #1 Appliance Company*, trusted by millions of families nationwide. We manufacture and sell products under the Monogram™, Café™, GE Profile™, GE®, Haier™, and Hotpoint™ brands. Our operations support nearly 98,000 additional American jobs and represent an investment of more than $3.5 billion since 2016. We are deeply committed to the communities where we live and work, passionate about getting closer to our product users to understand their needs and driven by the belief that there's always a better way. To learn more about our company, brands, career opportunities, and impact, visit or connect with us on LinkedIn. *OpenBrand Consumer Tracking Survey, Q1 – Q4 2024, Based on Volume of Total Majors/MO/RAC – Retail Units Media Contact Dawn Bramblett, Bramblett Group, 731-608-7650, dawn@ View original content to download multimedia: SOURCE Bramblett Group Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
C Spire Named 2025 Southeast Partner of the Year by Arctic Wolf
Ridgeland-based Business Receives Honor from Global Leader in Security Operations RIDGELAND, Miss., June 11, 2025--(BUSINESS WIRE)--C Spire has been named Arctic Wolf Southeast Partner of the Year for 2025. This recognition highlights the company's exceptional leadership in cybersecurity, outstanding service delivery, and commitment to helping mutual customers drive innovation and achieve stronger security outcomes. "We are honored to be recognized as Arctic Wolf Southeast Partner of the Year and look forward to delivering even more cybersecurity innovation and value for our customers," said Drake Cushing, Senior Vice President and General Manager for C Spire Business. "Cybersecurity threats and their constant advancement in attack methods continue to grow and require forward-focusing technology to protect businesses. Through our partnership with Arctic Wolf, C Spire continues to deliver advanced technology our customers need and expect from us." The Arctic Wolf Partner of the Year Awards recognize elite partners who have demonstrated outstanding leadership in helping organizations improve their security operations through Arctic Wolf's portfolio of solutions. Now in their eighth year, the honors celebrate top-performing companies that have shown excellence in security practice, executive alignment, revenue growth, and service. "This year's award winners represent the very best of the Arctic Wolf partner community," said Will Briggs, Senior Vice President, Global Channels, Arctic Wolf. "Each of these organizations has demonstrated exceptional commitment to our shared mission to end cyber risk, helping customers navigate an increasingly complex threat landscape with confidence and resilience. We're proud to recognize their achievements and celebrate the critical role they play in driving meaningful security outcomes." C Spire Business is a division of C Spire, a diversified telecommunications and technology services provider. C Spire has highly certified IT engineering talent in markets across the Southeast U.S. and specializes in connecting businesses of all sizes with best-in-class solutions. Cloud, collaboration, cybersecurity, managed IT, fiber connectivity — C Spire Business delivers all the power and expertise organizations need to win. As organizations worldwide face an increasingly complex threat landscape and a persistent cybersecurity talent shortage, over 10,000 organizations globally now rely on the Arctic Wolf Aurora Platform to help end cyber risk. Built on an open-XDR architecture and powered by Alpha AI™ technologies, the Aurora Platform is designed to deliver positive security outcomes at scale. Each week, it ingests, parses, enriches, and analyzes over eight trillion security events—transforming overwhelming volumes of data into an average of just one actionable alert per customer per day. Additional Resources For more information about C Spire, visit For more information about Arctic Wolf, please visit About C SpireC Spire is a diversified telecommunications and technology services company that provides a full suite of dedicated internet, wireless, IP Voice, data, cloud and managed IT services for businesses and enterprises, world-class, customer-inspired wireless communications, as well as fiber internet for consumers. This news release and other announcements are available at For more information about C Spire, visit or follow us on Facebook at or X at View source version on Contacts Press Contact C SpireCourtney Grimes, 601-746-2737cgrimes@
Yahoo
an hour ago
- Yahoo
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), held its Combined General Meeting (the 'General Meeting'). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Viaskin and EPIT are trademarks of DBV Technologies. Investor Contact Katie MatthewsDBV Media ContactAngela Marcucci DBV Attachment PDF VersionFehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
